VioQuest Pharmaceuticals, Inc. Initiates Clinical Trial For Akt Targeted Therapeutic

BASKING RIDGE, N.J., May 24, 2006 (PRIMEZONE) -- VioQuest Pharmaceuticals (OTCBB:VQPH), a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, has initiated a Phase I/IIa clinical trial to assess the safety and dosing of VQD-002, triciribine-phosphate (TCN-P). This trial is being conducted in up to 20 patients with diverse solid tumors, where abnormal levels of phosphorylated Akt (protein kinase B) have been observed. The co-inventors for VQD-002 are Dr. Said M. Sebti and Dr. Jin Cheng from The University of South Florida H. Lee Moffitt Cancer Center and Research Institute.